reason report
bottom line yesterday alder report fy financi
result updat investor progress lead asset
eptinezumab recent submit fda approv
migrain prevent bla submiss eptinezumab
formal complet februari suggest compani
hear back accept applic end
april see compani first bla accept de-risk event
alder stock given timelin develop uncertainti
overhang compani much last month
believ alder competit posit partner
and/or acquisit discuss bla accept
pdufa data set timelin suggest eptinezumab
inject anti-cgrp medicin reach market earli
call yesterday alder spent consider time effort build
investor interest second migrain treatment
candid approach clinic compani declin answer
whether product would produc compani controversi
yeast product system suggest virtu target
pacap ligand rather one three receptor might
posit outcom mp defunct program
controversi call compani continu
expens futur profit newli disclos five-year
suppli agreement sandoz appear guarante capac doesnt
appear come cheapli alder explain jump
 like continu base up-front
cost new arrang compani also refus discuss
potenti long-term profit product like
saddl signific royalti oblig teva mp
also contract manufactur cost sandoz given uncertainti
futur profit franchis increas
expect product cost also increas near-term
expens forecast chang reduc dcf-base valuat
although maintain outperform rate alder
stock long-term expect compani sensibl
tuck-in acquisit number larg cap biopharma compani
neurolog franchis ambit
look ahead next catalyst alder stock
anticip fda accept eptinezumab bla late april
fda respond within day date file feb
time expect alder would receiv pdufa date
around alder also expect initi first-in-human studi
monoclon antibodi target end
throughout expect investor continu follow
per share net cash per share end
share outstand mil
year price history/av daili volume mil aldr
compani inform svb leerink llc research
revenu mm ep present
pleas refer page import disclosur price chart analyst certif
prescript trend cgrp class continu show robust
uptak note
alder report net loss expect
driven higher spend relat stock eptinezumab
commerci suppli total expens
quarter total compar expect
consensu respect
sg alder end fourth quarter
similar share count cash balanc
compar expect cash balanc
made small updat expens forecast result
modest reduct price target given higher
 rate likelihood trend continu
compani build commerci suppli eptinezumab increas
 forecast also increas
 expens time period accur captur
current trajectori chang price target
share previous maintain outperform rate
rate aldr share outperform alder biopharmaceut late stage biotechnolog
compani guid develop lead product eptinezumab monoclon antibodi
seek prophylax migrain eptinezumab member larg emerg class
anti-cgrp anti-calcitonin gene relat peptid cgrp area heavi competit
partner nv teva aldr announc posit data two pivot
studi migrain prophylaxi recent file bla epti
us potenti approv launch earli across anti-cgrp group aldr
compani develop iv though expect patient prefer at-hom
administr believ defined/differenti market exist durabl in-offic infus
physician make money
estim price target aldr month use dcf analysi dcf
valuat employ discount rate termin growth rate believ
discount rate reason consid clinic stage compani dcf valuat
includ net cash dilut secur addit forecast cash flow believ
eptinezumab grow time achiev global risk-adjust sale
includ royalti outsid us includ probability-of-success iv
peak market share anti-cgrp market
risk valuat includ fda/ema approv risk eptinezumab risk
clinic program delay competit risk given presenc multipl anti-cgrp
antibodi manufactur risk risk disappoint clinic data risk dilut
 incl payment teva
svb leerink compani file zack factset consensu
ip royalti teva
licens clazakizumab
net incom loss equiti
dividend pref convert
net incom loss common
sec file svb leerink
alder bs cf mm
chang
sec file svb leerink
termin valu discount
sec file svb leerink llc
fda accept bla file
